Jonathan Davis, MD, MPHS on heart failure care’s guidelines barrier.

Cardiology Guidelines

HFrEF Treatment’s Guideline Barrier

Guideline-directed medical therapies (GDMT) for heart failure have proven to be “profoundly effective at reducing morbidity and mortality,” and yet prescription rates for many HFrEF therapies are far too low and inconsistent.

To unravel this challenge, a UCLA team analyzed VA data from 178k veterans in 306 Hospital Referral Regions (HRRs) across the US.

On a national level, the researchers observed low median nationwide prescription rates for many key HFrEF drug classes, but relatively high rates for others:

• Beta-blockers – 80%
• ACEI/ARB/ARNI – 69.3%
• MRA – 29.2% (some seemed particularly concerned about this)
• ARNI – 12.2%
• SGLT2I – 10.3%

A deeper dive into these numbers reveals even greater regional variations, finding:

• Wide variations across HRRs nationwide and within geographic regions
• An inverse association between prescription rates and income inequality
• A strong association between prescription rates and access to cardiology clinics
• A strong association between prescription rates and VA telehealth use

Noting that drug costs are less of an issue with VA patients, the study and related editorial paid special attention to the role that cardiology clinic and telehealth access played in GDMT compliance. 

• 60% of HRRs in the top 10% of cardiology clinic visits had above-median GDMT rates
• 7 of the 10 HRRs with the lowest prescription scores didn’t have a VA cardiology clinic
• 67% of HRRs in the top 5% of cardiology telehealth visits had above-median GDMT rates
• 8 of the 10 HRRs with the lowest prescription scores didn’t have any VA cardiology telehealth visits

Given the significant variations within this single health system, and the importance of GDMT adherence, the study and editorial authors proposed a long list of targeted strategies to improve overall heart failure care:

• Forming multidisciplinary heart failure management team
• Making guidelines universally available and implementable
• Seamlessly implementation GDMT into provider workflows, especially the EHR
• Increased HF medication education, focused on prescription and uptitration 
• Dedicating more resources to social determinants of HF health 
• Expanding access to cardiology clinics and telehealth

The Takeaway

Heart failure treatments and diagnostics have come a long way in recent years, but this study illustrates the important role that GDMT compliance will play in order for those major scientific advancements to have a similarly major impact on patient care.

The Holy Grail of Heart Attack Prevention

See how CCTA AI can transform preventive heart care far beyond CAC scoring, in this upcoming Cleerly webinar featuring world-renowned prevention expert Dr. Arthur Agatston (author of the South Beach Diet, creator of the Agatston score), Cleerly founder Dr. James Min, and CMO Dr. James P. Earls. Here’s where you can register today in order to join live on May 12th.

PIA’s Post-Processing Solution

Advanced cardiac imaging often calls for a time-consuming post-processing step, requiring costly software, hardware, and training. See how PIA provides this post-processing at lower cost, improved consistency, and greater efficiency.

The Wire

• Apple Watch X Might Add BP: Apple might have finally cracked the code on the holy grail of wearable health tech: blood pressure tracking. Bloomberg reports that the long-awaited feature will make its debut in the forthcoming “Watch X,” which is expected to bring the biggest overhaul in the Apple Watch’s history, and will supposedly fit BP tracking into a significantly thinner watch by redesigning its strap locking mechanism.

• Less is More for Home BP Testing: Seven days of home blood pressure monitoring is usually advised to confirm hypertension diagnosis, but a new study finds that three days or less is usually enough. Among 361 patients not on BP-lowering drugs, home monitoring confirmed high blood pressure in 38% of patients. The vast majority of those hypertensive patients would have been confirmed in one, two, or three days (63.7%, 80.8%, 91.3%), while only 1.4% would require more than 6 days.

• Flatlining with Wearable Defibrillators: A new analysis of the FDA’s MAUDE device database found that flatlining (asystole) was common among patients who died after a shock from wearable converter-defibrillators (WCDs). Among 313 patients who died out-of-hospital after a WCD shock for VF, VT and non-VF/VT rhythms, 65.2% experienced asystole and 35.5% had bradycardia. The researchers concluded that implanted pacemakers may not prevent asystole shock and suggested exploring back-up pacing options.

• Hospitals Among Most Dangerous Workplaces: About 3 in 4 nonfatal workplace violence injuries now involve workers in healthcare and social work, making hospitals and clinics the most dangerous workplaces in the US. Healthcare workers suffer more nonfatal injuries from workplace assaults than any other field – including law enforcement – and backlash against pandemic public health measures isn’t helping the situation. Healthcare saw 10.4 injuries from workplace violence per 10k workers in 2018, up 62% from 2011.

• Argus Cognitive’s RV Approval: Argus Cognitive landed FDA 510(k) premarket approval for its ReVISION Software, which analyzes 3D echo exams to help cardiologists discover and risk stratify hidden right ventricular dysfunction. ReVISION is one of the few solutions supporting RV echo analysis, and reportedly the only solution that allows clinicians to fully characterize RV function using 3D echocardiography, while joining a range of LV-targeted echo solutions.

• GLP-1 Patent Push: The pharma companies leading the obesity care overhaul with GLP-1 drugs are lawyering up to stretch their protection against generic competition. The manufacturers for 10 of the top GLP-1 medications filed a median of 19.5 patents for each product and secured 18.3 years of expected protection. Half of the protections were related to the drugs’ delivery device as opposed to the drugs themselves, and plenty more patents could be on the way.

• Reassuring Results for S-ICD in CHD: Results from the HONEST study supports the safety and effectiveness of subcutaneous ICDs in patients with congenital heart disease (CHD). Among 4,924 patients with Boston Scientific’s Emblem implants (101 w/ CHD), researchers found that 15.8% of patients with CHD received at least one appropriate shock, and all of those shocks were successful. Annualized complication rates were similar for CHD and non-CHD patients (8.7% vs. 7%; HR: 1.2).

• Ventripoint & Ascend Integrate: Echo AI company Ventripoint Diagnostics announced its integration with Ascend Cardiovascular’s diagnostic viewer and structured reporting applications, creating an end-to-end echo workflow. The alliance continues Ascend’s increased focus on echo AI partnerships, coming roughly four months after launching an integration with Us2.ai.

• Does ART Damage the Heart? A large Nordic registry study suggests that it doesn’t. Analysis of 2.5M women who gave birth and were followed for 11 years, including 4% who received assisted reproductive technologies (ART; fertility treatments), found that the ART cohort didn’t have significantly increased CVD risks and actually had lower risk of heart attack (AHR 0.80). The ART cohort also had no greater risks of stroke and ischemic and cerebrovascular disease, although there was weak evidence of a link between frozen embryo transfers and stroke.

• Keeping Astronauts’ Hearts Safe: Cardiac atrophy might be a fact of life aboard the International Space Station, but astronauts’ current workout regimen is enough to limit space’s impact. The study analyzed 13 astronauts who exercised for at least 1.5 hours per day while aboard the ISS for an average of 133 days. The astronauts’ cardiac work (based on BP) fell by 12% during flight, but they showed no meaningful difference in LV mass (115 g pre-flight vs. 118 g post-flight) and no major changes across other heart health metrics.

• Doctors’ Hidden Fee: A ProPublica exposé told the brutal tale of how it became common practice for payors to require doctors to fork up a 5% fee in order to be paid electronically. The story is told through the lens of payment processor Zelis’ lobbying efforts against CMS, revealing how the company splits the revenue with payors while saddling doctors with another cost. Spoiler alert: CMS now believes its oversight extends only to payors, not to their “business associates.”

Save your spot: Unlock the Secrets of Cusp Overlap on Pre-existing Rhythm Disorders on August 22!

Join us on August 22 at 8:00 p.m. ET for the highly anticipated live master class with esteemed expert, Dr. Hemal Gada. Renowned for his expertise, he’ll walk you through the intricacies of the Cusp Overlap Technique in patients with pre-existing rhythm disorders over the course of 55 minutes. Don’t miss it!

User Experience and Cardiovascular Imaging Transformation

Check out this Change Healthcare video discussing the importance of user experience in the adoption of structured reporting, and how it can lead to improvements in imaging speed, quality, and cardiologist workflow. 

The Resource Wire

• HeartFlow’s PRECISE trial showed that their precision approach for evaluating stable chest pain avoids unnecessary testing and improves care – without risking missed heart disease diagnoses. In this Cardiac Wire Show, HeartFlow’s Chief Medical Officer Dr. Campbell Rogers dives into the PRECISE trial results and its implications for clinical practice.

• QRS detection is essential for any ECG algorithm, and Monebo’s Kinetic QRS ECG Algorithm sets the standard for accuracy. Kinetic QRS accurately detects the QRS complex, no matter the amplitude, waveform, or noise levels.

• The University College London National Amyloidosis Centre is the world’s largest cardiac amyloidosis care provider, making their echo assessments both crucial and high-labor. See how UCL researchers used Us2.ai’s AI echo software to accurately analyze echos from 1,200 patients with ATTR Amyloidosis in 24 hours, without requiring human interaction.